EMERGENT ANNOUNCES TYPHOID VACCINE STUDY RESULTS

Emergent BioSolutions announced positive results from a Phase II clinical study evaluating a new simplified dosing regimen for the company's next generation single-dose oral typhoid vaccine. The results of the study were published in the August edition of the Journal of Infectious Diseases.

The Phase II study evaluated the safety and immunogenicity of the vaccine in 32 healthy adult volunteers. The study demonstrated that utilization of a simpler more rapid dosing regimen did not affect the excellent safety profile or the magnitude of the immune response stimulated by the vaccine. Previously, a single dose of the oral typhoid vaccine was shown to be safe, well tolerated and highly immunogenic in human volunteers when using a lyophilized product suitable for commercialization.